Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients

被引：0
|
作者：
Jean Claude Alvarez
Pierre Moine
Benjamin Davido
Isabelle Etting
Djillali Annane
Islam Amine Larabi
Nicolas Simon
机构：
[1] Raymond Poincaré Hospital,Department of Pharmacology and Toxicology, Paris
[2] AP-HP,Saclay University (Versailles Saint
[3] Hôpital Raymond Poincaré,Quentin
[4] AP-HP,en
[5] Raymond Poincaré hospital,Yvelines), Inserm U
[6] AP-HP,1173, FHU Sepsis
[7] Raymond Poincaré hospital,Laboratoire de Pharmacologie
[8] AP-HP,Toxicologie, Université de Versailles Saint
[9] Aix-Marseille University,Quentin
来源：
European Journal of Clinical Pharmacology | 2021年 / 77卷
关键词：
Lopinavir; Pharmacokinetics; Covid-19;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：389 / 397
页数：8
相关论文
共 50 条
  • [31] Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
    Zanon, D.
    Musazzi, U. M.
    Manca, A.
    Nicolo, A. De
    D'Avolio, A.
    Cilurzo, F.
    Maximova, N.
    Tomasello, C.
    Clementi, E.
    Minghetti, P.
    DATA IN BRIEF, 2020, 33
  • [32] Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
    Dario Cattaneo
    Mario Corbellino
    Cristina Gervasoni
    European Journal of Clinical Pharmacology, 2021, 77 : 791 - 792
  • [33] Consultation psychiatry in COVID-19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs
    Marcatili, Matteo
    Stefana, Alberto
    Colmegna, Fabrizia
    di Giacomo, Ester
    D'Amico, Emiliano
    Capuzzi, Enrico
    Dakanalis, Antonios
    Clerici, Massimo
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (04) : 145 - 146
  • [34] Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
    Echarte-Morales, Julio
    Minguito-Carazo, Carlos
    del Castillo-Garcia, Samuel
    Borrego-Rodriguez, Javier
    Rodriguez-Santamarta, Miguel
    Sanchez-Munoz, Enrique
    Bergel-Garcia, Ruben
    Gonzalez-Maniega, Clea
    Prieto-Gonzalez, Silvia
    Menendez-Suarez, Paula
    Tundidor-Sanz, Elena
    Benito-Gonzalez, Tomas
    Fernandez-Vazquez, Felipe
    JOURNAL OF ELECTROCARDIOLOGY, 2021, 64 : 30 - 35
  • [35] Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
    Binois, Yannick
    Hachad, Hafsah
    Salem, Joe-Elie
    Charpentier, Julien
    Lebrun-Vignes, Benedicte
    Pene, Frederic
    Cariou, Alain
    Chiche, Jean-Daniel
    Mira, Jean-Paul
    Nguyen, Lee S.
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (10): : 1787 - 1790
  • [36] Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
    Cattaneo, Dario
    Corbellino, Mario
    Gervasoni, Cristina
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (05) : 791 - 792
  • [37] Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
    Schneider, Johanna
    Jaenigen, Bernd
    Wagner, Dirk
    Rieg, Siegbert
    Hornuss, Daniel
    Biever, Paul M.
    Kern, Winfried V.
    Walz, Gerd
    PLOS ONE, 2021, 16 (05):
  • [38] Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series
    Lepage, Marc-Antoine
    Rozza, Nicholas
    Kremer, Richard
    Grunbaum, Ami
    CLINICAL TOXICOLOGY, 2021, 59 (07) : 644 - 647
  • [39] Lopinavir-ritonavir versus darunavir-norvir for hospitalized COVID-19 patients
    Paroczai, Dora
    Bikov, Andras
    Blidaru, Andreea
    Bobu, Emanuel
    Cerbu, Bianca
    Marincu, Iosif
    Mihaicuta, Stefan
    Frent, Stefan
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [40] Efficacy and Safety of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir in Hospitalized COVID-19 Patients: A Randomized Clinical Trial
    Siami, Zeinab
    Dehghan, Danial
    Khavandegar, Armin
    Lak, Mehran
    Bakhtiyari, Mahmood
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2022, 24 (05)
12345